Previous close | 301.33 |
Open | 302.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 302.00 - 306.83 |
52-week range | 298.00 - 430.00 |
Volume | |
Avg. volume | 6,596 |
Market cap | 245.728B |
Beta (5Y monthly) | 0.21 |
PE ratio (TTM) | 16.14 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 9.97 (3.24%) |
Ex-dividend date | 17 Mar 2022 |
1y target est | N/A |
Roche's (RHHBY) performance in 2022 was sub-par as demand for COVID-19-related products declined significantly and 2023 will also be impacted.
Roche warned on Thursday profits will decline in 2023 as falling demand for its COVID-19 therapy and diagnostics kits will knock sales by over $5 billion, the latest sign that the pharmaceutical industry's years-long pandemic boost is ebbing. Sales and core earnings per share were expected to decrease at a "low single-digit" percentage this year, the Swiss pharmaceuticals and diagnostics company said in a statement. COVID-related sales, mainly from lab testing and antibody treatment Ronapreve, are seen falling by 5 billion Swiss francs ($5.5 billion) for the full year, it said.
Roche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating early-stage hepatocellular carcinoma, meets its primary endpoint.